Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Biomedomics Inc. is actively prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions, both of which are assigned to 1 distinct examiner. This concentration indicates that the company's current interactions with the patent office are centralized through a single point of review within 1 distinct art unit. Such a structure allows for a very consistent prosecution approach across the company's active biotechnology applications.
The busiest examiner for Biomedomics Inc. is MARCSISIN, ELLEN JEAN, who is managing 2 pending office actions. This examiner is responsible for the entirety of the company's pending workload in the Biotechnology & Pharmaceuticals sector. For practitioners, this means that the immediate prosecution strategy and potential for allowance are heavily dependent on the specific requirements and examination style of this individual within the identified art unit. The lack of examiner diversity means that any trends or preferences shown by this examiner will apply to all of the company's currently pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARCSISIN, ELLEN JEAN | 2 | 34.6% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18662553 | LATERAL FLOW IMMUNOASSAY METHOD OF SIMULTANEOUSLY DETECTING HEMOGLOBIN S, HEMOGLOBIN C, AND HEMOGLOBIN A IN NEWBORNS, INFANTS, CHILDREN, AND ADULTS | MARCSISIN, ELLEN JEAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18662553 | LATERAL FLOW IMMUNOASSAY METHOD OF SIMULTANEOUSLY DETECTING HEMOGLOBIN S, HEMOGLOBIN C, AND HEMOGLOBIN A IN NEWBORNS, INFANTS, CHILDREN, AND ADULTS | MARCSISIN, ELLEN JEAN | — |
| 14725894 | LATERAL FLOW IMMUNOASSAY METHOD OF SIMULTANEOUSLY DETECTING HEMOGLOBIN S, HEMOGLOBIN C, AND HEMOGLOBIN A IN NEWBORNS, INFANTS, CHILDREN, AND ADULTS | MARCSISIN, ELLEN JEAN | — |
| Art Unit | Apps |
|---|---|
| 1677 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18662553 | LATERAL FLOW IMMUNOASSAY METHOD OF SIMULTANEOUSLY DETECTING HEMOGLOBIN S, HEMOGLOBIN C, AND HEMOGLOBIN A IN NEWBORNS, INFANTS, CHILDREN, AND ADULTS | MARCSISIN, ELLEN JEAN | 1677 | §101§103 | Non-Final OA | — | Pending | May 13, 2024 |
| 14725894 | LATERAL FLOW IMMUNOASSAY METHOD OF SIMULTANEOUSLY DETECTING HEMOGLOBIN S, HEMOGLOBIN C, AND HEMOGLOBIN A IN NEWBORNS, INFANTS, CHILDREN, AND ADULTS | MARCSISIN, ELLEN JEAN | 1677 | §103 | Final Rejection | — | Pending | May 29, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiomedomics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ellen Jean Marcsisin has the most, with 2 of Biomedomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
